Multiple Patient Program to Ensure Access to LCZ696 Treatment to Patients Diagnosed With Heart Failure With Reduced Ejection Fraction (HF-rEF)
Phase of Trial: Clinical Phase Unknown
Latest Information Update: 31 Jan 2018
At a glance
- Drugs Sacubitril/valsartan (Primary)
- Indications Heart failure
- Focus Expanded access; Therapeutic Use
- Sponsors Novartis; Novartis Pharmaceuticals
- 27 Oct 2016 Status changed from completed to recruiting.
- 01 Oct 2015 Status changed from recruiting to completed as per ClinicalTrials.gov record.
- 19 Mar 2015 New trial record